Mounties on aristolochic acid watch
This article was originally published in The Tan Sheet
Executive Summary
Health Canada asks the Canadian Border Services Agency to prevent the importation of aristolochic acid-containing products and advises consumers not to use the "naturally occurring toxin that can cause cancer, mutations in human cells and end-stage kidney failure." Health Canada first issued a warning about the ingredient in 1999 and is "determining whether these products are being sold on the Canadian market," the agency notes July 26. FDA issued an import alert in 2000 for detention of aristolochic acid products 1("The Tan Sheet" July 17, 2000, In Brief)...
You may also be interested in...
Aristolochic acids
FDA issues import alert #54-10 July 6 authorizing the detention of products containing aristolochic acid. The alert also notes products labeled as containing Stephania, Clematis, Cocculus, Akebia, Asarum, Bragantia, Diploclisia, Menispernum or Sinomenium may be detained due to possible mistaken substitution of these plants with Aristolochia. FDA noted its intention to issue an import alert in a May 16 letter to industry (1"The Tan Sheet" May 29, p. 10). The substance, found in Chinese herbal remedies, has been linked to reports of kidney failure
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.